ClinicalTrials.gg
Active, not recruitingNCT02923570Updated Nov 5, 2026

Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Head and Neck Cancer

A Phase 2 interventional study of Photon intensity modulated radiation therapy (IMRT) and Proton beam radiotherapy (PBRT) in Head and Neck Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center — 6 open to participants now, 11 under way, none of them phase 3. Head and Neck Neoplasms · Memorial Sloan Kettering Cancer Center.

Enrollment
3rd of 32
108 · median 28
Started
2016
the only one that year
Phase 2
16 of 52
1 open now
Primary completion
2027-10
later than 9 of 10 live
Registered
39th of 52
by date

Among the 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 3rd largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2016, is one of 16 in phase 2, reaches primary completion later than 9 of the 10 other live ones, and was the 39th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

6 of the 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

Compared to IMRT, PBRT is thought to give less radiation exposure to the surrounding healthy tissues. It is possible that side effect rates with PBRT will be lower or the same compared to IMRT, but this has not been well studied to date. Although both of these radiation therapies have been used in the past to treat head and neck cancer, this research study will compare the effects of these two different radiation treatment modalities with each other to see whether PBRT is better, the same or worse than IMRT.

03

Conditions studied

  • Head and Neck Cancer

Keywords

  • proton-beam radiation therapy (PBRT)
  • intensity-modulated radiation therapy (IMRT)
  • 16-1416
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 18.
  • Histopathologically confirmed diagnosis of one the following cancer types:

    • Salivary gland cancer
    • Skin cancer
    • Melanoma
  • HNSCC that require ipsilateral radiation
  • Patients must be a candidate for ipsilateral radiation therapy.
  • performance status ≥70.
  • Negative pregnancy test for women of (\<51 years of age) as per institutional policy.

Exclusion criteria

Exclusion Criteria:

  • Any prior head or neck irradiation.
  • Physician recommendation of bilateral neck radiation.
  • Non-resectable disease
  • Physician recommendation of mucosal radiation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Photon intensity modulated radiation therapy (IMRT)

    IMRT to standard dose of 60-66Gy

    Radiation: Photon intensity modulated radiation therapy (IMRT)

  • Experimental
    Proton beam radiotherapy (PBRT)

    PBRT to standard dose of 60-66Gy

    Radiation: Proton beam radiotherapy (PBRT)

Interventions

  • RadiationPhoton intensity modulated radiation therapy (IMRT)

    Photon intensity modulated radiation therapy (IMRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.

  • RadiationProton beam radiotherapy (PBRT)

    Proton beam radiotherapy (PBRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.

06

What researchers measure

Primary outcomes

  1. number of patients with grade 2 or greater acute mucositis

    via the CTCAE v4.0.

    Time frame: 1 year

07

Study locations

9 sites
08

References and documents

Publications

  • Dee EC, Kalman NS, Ma DJ, Lester SC, Zhang Z, Gelblum D, Yu Y, Chen L, McBride SM, Riaz N, Mueller BA, Shamseddine A, Zakeri K, Kang JJ, Tsai CJ, Wu Y, Mah D, Sine K, Shim A, Lin H, Ho A, Wong RJ, Romesser PB, Barker CA, Lee NY. A phase II randomized study of proton therapy vs intensity-modulated radiation therapy in patients with unilateral head and neck cancer. J Natl Cancer Inst. 2026 Sep 3:djag257. doi: 10.1093/jnci/djag257. Online ahead of print. PubMed 42690689 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2016 (actual). Primary completion is estimated for Oct 2027, 132 months after the start.

Of 219 non-industry phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's planned 132 months is above that.

Counting every sponsor, half of 263 studies reached it within 51 months; a quarter within 30 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2016
First posted
Oct 4, 2016
StartActual
Oct 3, 2016
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Oct 2027was Oct 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Oct 2027
Nov 5, 2026
Study completion
Oct 2026→Oct 2027
Nov 5, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42690689 ↗
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42690689 ↗
    Primary completion Oct 2026→Oct 2027
    Study completion Oct 2026→Oct 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02923570
Collaborators
Mayo Clinic
Responsible party
Sponsor
First posted
Oct 4, 2016
Start date
Oct 3, 2016
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Nancy Lee, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion